Open AccessPrognostic and clinicopathological value of high expression of TIM ‐3 in different cancer types: A meta‐analysis
Author(s) -
Xu Wenbo,
Qi Feng,
Jiao Ruidi,
Zheng Lizhuan,
Zhang Yinghao,
Hou Donghai,
Liu Yi,
Kang Zhengjun
Publication year - 2020
Publication title -
precision medical sciences
Language(s) - English
Resource type - Journals
ISSN - 2642-2514
DOI - 10.1002/prm2.12007
Subject(s) - medicine , hazard ratio , cancer , oncology , lung cancer , esophageal cancer , subgroup analysis , meta analysis , biomarker , lymphoma , breast cancer , confidence interval , liver cancer , biology , biochemistry
Abstract Background This meta‐analysis was performed to clarify the prognostic role of the expression of T‐cell immunoglobulin mucin‐3 (TIM‐3) in different cancer types. Methods Related articles were searched from PubMed, EMBASE, Web of Science up to December 31, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were utilized to explore their associations. In addition, we conducted subgroup analyses stratified by various factors. Results Eventually, a total of 33 studies including 4223 patients were enrolled in this study. Results showed that patients with high TIM‐3 expression had shorter overall survival (OS) (HR = 1.67, 95% CI: 1.37‐2.04) and progression‐free survival (HR = 1.80, 95% CI: 1.14‐2.83), but subgroup analyses indicated there were no relationship between TIM‐3 expression and disease‐free survival or recurrence‐free survival. It was reassuring that high TIM‐3 expression may be associated with poor prognosis in osteosarcoma, gastric cancer, liver cancer, esophageal cancer, and lymphoma, while no prognostic significance was detected of TIM‐3 expression in lung cancer, kidney cancer, or breast cancer. Furthermore, we did not find association of TIM‐3 with any clinicopathological parameters. Conclusions High TIM‐3 expression might be a potential biomarker which can be used to predict the poor prognosis of different cancer types, especially osteosarcoma, gastric cancer, liver cancer, esophageal cancer, and lymphoma.